Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut

Corteva (CTVA) reported Q3 2026 adjusted earnings of $0.06/share, missing estimates, and revenues of $1.52B, also below consensus. The company cut its full-year EBITDA outlook to $1.1B-$1.13B due to Brazil's inventory issues, pricing pressure, and volume declines. CEO Luther Kissam and CFO Jeffrey Rudolph highlighted inventory normalization and cost reductions as priorities, with a focus on new products for growth. Full-year earnings are now projected at $0.76-$0.80/share.

Original reporting
Published Nov 13, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Corteva Q3 Earnings Call Highlights Brazil Woes and Outlook Cut — source image
Decision brief

The 30-second read

$CTVABearishMed
01

Why it matters

The guidance cut is the primary new information, likely driving short‑term downside.

02

Market read

First report of a material earnings guidance reduction for a mid‑cap agribusiness firm, creating actionable downside risk.

03

What to watch

Cost‑reduction program and new product volume growth may offset Brazil weakness over the next quarters.

Relevance 7/10Novelty 8/10Timing: post‑market

Background

Corteva reported Q3 2026 results with earnings miss and lowered full‑year outlook due to Brazil inventory and pricing issues.

Company-level read

Ticker impact

$CTVABearishHigh confidence
Context

Corteva cut its full-year adjusted EBITDA outlook to $1.1‑$1.13 bn, citing Brazil weakness and $100 m inventory impact.

Expected impact

downward pressure as investors price in lower EBITDA and revenue guidance

Evidence & confidence

The new guidance is materially lower than prior expectations and directly tied to a major market (Brazil), likely prompting a sell‑off.

Market effects

Agricultural chemicals sector faces earnings pressure from Brazil exposure.

Brazilian agribusiness outlook may weigh on related commodity and input stocks.

Potential ripple to global ag‑input supply chain and cost‑inflation dynamics.

Counterpoint

If Brazil inventory normalizes faster than expected, Corteva could rebound and exceed revised guidance.

Key entities

  • Corteva, Inc.

    US‑listed agricultural chemicals producer (CTVA).

Related articles

$CTVAMedAI 8/10

Mizuho cuts Corteva stock price target to $13 on Brazil woes

Mizuho cut Corteva's (CTVA) price target to $13 from $16, citing Brazil market woes and reduced EBITDA guidance. CTVA shares fell 22% last week, trading near a 52-week low. The company's Q3 earnings missed estimates, with a 33% drop in operating EBITDA. RBC and Oppenheimer also lowered targets and ratings, citing execution challenges and Brazil headwinds.

$CTVAMedAI 8/10

Corteva Q3 Earnings Call Highlights

Corteva (CTVA) reported Q3 sales of $5.4B, down 1%, with operating EBITDA flat at $943M. Growth in North America, EMEA, and Asia Pacific offset pressure in Brazil, where market sellout was down 12% YTD. CEO Kissam discussed cost-cutting measures, including a hiring freeze and R&D project reviews. The company expects 2027 growth and share repurchases, with $1.8B cash on hand at Q3 end. New products Arylex and Pyraxalt saw over 20% volume growth, with combined annual revenue of $650M.

$CTVAMedAI 8/10

Corteva Inc (CTVA) Q3 2026 Earnings Call Transcript

Corteva Inc. (CTVA) reported Q3 2026 earnings, with net sales at $1.6B, down 9% YoY, and operating EBITDA at $222M, down 17%. Growth was seen in North America, EMEA, and Asia Pacific, but Latin America sales dropped 31% due to market challenges. The company maintained flat EBITDA levels YoY and expanded margins despite $230M in pricing headwinds. Corteva declared its first quarterly dividend and remains on track for a year-end cash position of $1.5B.